ABSTRACT
Esperion had just announced very positive clinical data for its lead candidate, and its novel method of addressing high cholesterol was generating interest in both the scientific and business communities. Was now the right time to sell, or should Esperion push on and build itself into a fully-integrated biotech company? Was Pfizer the right suitor, or was there another company which could better help continue Esperion’s success? What would happen to Esperion if it was acquired-to the people who had founded and built the company, and developed the molecules so highly regarded today? Dr Newton turned his key and pulled out of Esperion’s parking lot. He had several weeks to evaluate Pfizer’s offer, and would need the time to think fully through his options.
